Cianfrocca C, Sabia R, Zoboli S, Bugiardini R
Istituto di Patologia Medica III, Policlinico S. Orsola, Bologna.
G Ital Cardiol. 1993 May;23(5):439-49.
The present multicentre study, conducted in patients with angina pectoris on chronic therapy with continuous 24-hour transdermal nitroglycerin was aimed at investigating: (1) the actual incidence of nitrate tolerance; (2) the clinical features that characterize those who do not develop tolerance; (3) whether the evidence of clinical and ergometer benefits at 1-month assessment predicts their long-term maintenance. Eligible patients (n = 110; average age 56 +/- 5 yrs) had stable angina pectoris (78 effort angina, 32 mixed angina) with symptom-limited, reproducible cycloergometer tests and were responsive to s.l. nitroglycerin. After a 7-day washout period and a placebo run-in week, all patients were assigned to continuous 10 mg/24-hour nitroglycerin patches (T0). Exercise tests were performed again after 1 month (T1) and 6 months (T6) of treatment. At T1, ergometric data in each patient were compared with those at T0 and showed an increase (> or = 15%) in exercise tolerance in only 61/110 patients: 38 (49%; Group A) of the 78 patients with effort angina and 23 (72%; Group B) of the 32 patients with mixed angina (p < 0.05). Those patients with no significant change in exercise tolerance were assigned to conventional antianginal therapy and were excluded from the study. At T6, both group A and B patients maintained the favourable effects on total exercise duration, time and maximum workload at ischemic threshold and maximal ST depression recorded at T1 vs T0. The weekly attacks of angina and nitroglycerin s.I. consumption decreased significantly in both Group A and Group B patients from the beginning of therapy and throughout the study. These results show that: 1) tolerance to continuous 24-hour transdermal nitroglycerin therapy is not constant phenomenon, but occurs only in a subgroup of patients; 2) patients with mixed angina are more resistant to develop tolerance than those patients with effort angina; 3) the 1-month evidence of clinical and ergometric benefits predicts their maintenance during long-term treatment, as well. These results allow one to hypothesize that the loss of nitrate efficacy on venous pooling capability, but not on arterial tone, might constitute the more frequent cause of tolerance.
本多中心研究针对接受24小时持续经皮硝酸甘油慢性治疗的心绞痛患者,旨在研究:(1)硝酸酯类耐受性的实际发生率;(2)未产生耐受性患者的临床特征;(3)1个月评估时临床和测力计检查显示的获益是否能预测其长期维持情况。符合条件的患者(n = 110;平均年龄56±5岁)患有稳定型心绞痛(78例劳力性心绞痛,32例混合性心绞痛),症状受限且可重复进行症状限制性踏车测力计试验,对舌下含服硝酸甘油有反应。经过7天的洗脱期和1周的安慰剂导入期后,所有患者均被分配使用持续10 mg/24小时的硝酸甘油贴片(T0)。治疗1个月(T1)和6个月(T6)后再次进行运动试验。在T1时,将每位患者的测力计数据与T0时的数据进行比较,结果显示,仅61/110例患者的运动耐量增加(≥15%):78例劳力性心绞痛患者中的38例(49%;A组)和32例混合性心绞痛患者中的23例(72%;B组)(p<0.05)。运动耐量无显著变化的患者被分配接受常规抗心绞痛治疗,并被排除在研究之外。在T6时,A组和B组患者在总运动持续时间、缺血阈值时的时间和最大工作量以及T1与T0相比记录的最大ST段压低方面均维持了有利影响。从治疗开始至整个研究期间,A组和B组患者的每周心绞痛发作次数和舌下含服硝酸甘油的消耗量均显著减少。这些结果表明:1)对24小时持续经皮硝酸甘油治疗的耐受性并非恒定现象,仅在部分患者亚组中出现;2)混合性心绞痛患者比劳力性心绞痛患者更不易产生耐受性;3)1个月时临床和测力计检查显示的获益也能预测其在长期治疗中的维持情况。这些结果使人们推测,硝酸酯类药物对静脉池功能而非动脉张力的疗效丧失可能是耐受性更常见的原因。